Acrivon Therapeutics, Inc.
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| – | – | – | – | – | – | |
| – | +6,300.0% | +31.6% | -51.1% | +87.7% | +34.8% | |
| – | – | – | – | – | – | |
| – | +633.6% | +74.6% | +89.9% | +40.7% | -6.3% | |
| – | +90.0% | +253.1% | +142.1% | +19.6% | -4.3% | |
| – | +410.9% | +101.8% | +104.2% | +32.2% | -6.2% | |
| – | – | – | – | – | – | |
| – | – | +2,425.4% | – | – | – | |
| – | – | – | – | – | – | |
| – | – | – | – | – | – | |
| – | – | – | – | – | – | |
| – | – | – | – | – | – |
Data as of: September 21, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.